Dose-dependant acute or subacute disease caused by *Burkholderia pseudomallei* strain NCTC 13392 in a BALB/c aerosol model of infection

S.G.P. Funnell, J.A. Tree, G.J. Hatch, S.R. Bate, G. Hall, G. Pearson, E.L. Rayner, A.D.G. Roberts and J. Vipond

National Infection Service, Public Health England (PHE), Salisbury, Wiltshire, UK

**Keywords**
aerosol, BALB/c, *Burkholderia*, dose, melioidosis, *pseudomallei*, subacute.

**Correspondence**
Simon G.P. Funnell, National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0GJ, UK. E-mail: simon.funnell@phe.gov.uk

2019/0625: received 9 April 2019, revised 21 June 2019 and accepted 25 June 2019
doi:10.1111/jam.14396

**Abstract**

**Aims:** The goal of this study was to examine, for the first time, the virulence and pathogenicity of aerosolized *Burkholderia pseudomallei*, strain NCTC 13392, in BALB/c mice in order to develop an animal model for testing novel medical countermeasures (MCMs) for the treatment of human acute and subacute (a disease state between acute and chronic) melioidosis.

**Methods and Results:** BALB/c mice were exposed to varying doses of aerosolized bacteria. Acute disease was seen in animals exposed to a very-high dose (≥10^3 CFU per animal) and death occurred 3–4 days postchallenge (pc). Bacteria were detected in the lungs, liver, kidney and spleen. In contrast, animals exposed to a low dose (<10 CFU per animal) survived to the end of the study (day 30 pc) but developed weight loss, a bacterial tissue burden and increasing clinical signs of infection from day 20 pc onwards, mimicking a subacute form of the disease. Pathological changes in the tissues mirrored these findings.

**Conclusions:** This proof of concept study has shown that *B. pseudomallei* strain NCTC 13392 is virulent and pathogenic in BALB/c mice, when delivered by aerosol. By varying the doses of aerosolized bacteria it was possible to mimic characteristics of both human acute and subacute melioidosis, at the same time, within the same study.

**Significance and Impact of the Study:** *Burkholderia pseudomallei*, the aetiological agent of melioidosis, causes a serious and often fatal disease in humans and animals. Novel MCMs are urgently needed for both public health and biodefense purposes. The present model provides a useful tool for the assessment and evaluation of new MCMs (e.g. therapeutics and vaccines) and offers the potential for testing new treatments for both subacute to chronic and acute melioidosis prior to human clinical trials.

**Introduction**

*Burkholderia pseudomallei*, the aetiological agent of melioidosis, causes a serious and often fatal disease in humans and animals (Titball *et al.* 2008). Despite the global widespread geographical occurrence of naturally acquired melioidosis, particularly in Southeast Asia and Northern Australia (Limmathurotsakul *et al.* 2016), there is no licensed vaccine and antibiotic therapy is problematic because *B. pseudomallei* is intrinsically resistant to many antibiotics (Wiersinga *et al.* 2006). Concerns over the use of *B. pseudomallei* as a biological weapon has resulted in this pathogen being classified as a Tier 1 Select Agent by the United States Federal Select Agent program (http://www.selectagents.gov/). Novel therapeutics and vaccines, otherwise known as medical countermeasures (MCMs), are needed for both public health and biodefense purposes.
Meliodosis can affect individuals with pre-existing health conditions such as diabetes mellitus (50% of cases) (Wiersinga et al. 2006). The disease can present a broad range of symptoms, with both acute and chronic phases. Acute disease can be severe with symptoms including fever, weight loss, pneumonia, sepsis and death (Currie et al. 2000; Boruah et al. 2013; Cheng et al. 2013; Jin and Ning, 2014). Chronic infection can be less severe and may present as abscesses distributed in single or multiple sites, including the spleen, lung, liver, joints and central nervous system (Wong et al. 1995; Kunnathuparambil et al. 2013; Liang et al. 2016). In addition, a latent or reactivated form of disease may appear years later: the longest recorded incubation period being 62 years (Ngauy et al. 2005). Humans can be infected naturally with B. pseudomallei following bacterial inoculation, inhalation or ingestion (Peacock et al. 2012). The route of infection and severity of disease are linked, with inhalation associated with a more rapid disease course (Tithall et al. 2008).

Treatment for melioidosis involves an intensive intravenous antibiotic infusion phase for a minimum of 10–14 days followed by a lengthy eradication phase of 3–6 months of oral antibiotic therapy (Pitman et al. 2015). Given the multidrug-resistant nature of B. pseudomallei to common antibiotics and the lengthy treatment regime for melioidosis, new MCMs are urgently needed. However, the protective efficacy of new therapeutics and vaccines are difficult to assess in Phase III human clinical trials because of the low incidence of naturally acquired B. pseudomallei in most parts of the world. It is also difficult to establish the exact route of entry of infection in human trials conducted in endemic countries. For this reason, well-characterized animal models of infection, with well-defined endpoints relevant to human disease will help evaluate the efficacy of novel MCMs for use in humans.

The mouse model of melioidosis is commonly used for prescreening the effectiveness of novel therapeutics before they are tested in larger animal models. Prior to evaluation, however, the decision about which mouse strain, the route of infection and which strain of B. pseudomallei to use is challenging as a variety of studies have been reported (Jeddeloh et al. 2003; Tithall et al. 2008; Lever et al. 2009; West et al. 2010; Conejero et al. 2011; Thomas et al. 2012; West et al. 2012; Lafontaine et al. 2013; Massey et al. 2014; Welkos et al. 2015; Trevino et al. 2018). Some studies show BALB/c mice to be more sensitive to infection with B. pseudomallei and thus help reflect acute human infection, while C57BL6 have been shown to be more resistant and thus mimic chronic infection (Leacey et al. 1998; Hoppe et al. 1999; Liu et al. 2002; Tan et al. 2008; Bearss et al. 2017; Trevino et al. 2018). Conversely, a chronic model of infection in BALB/c mice has been recently reported which utilizes a strain of B. pseudomallei 1106a, which has low virulence, delivered intraperitoneally (Amemiya et al. 2015). Among the reported mouse studies, a variety of delivery routes have been used (aerosol, intratracheal, intranasal, intravenous and intraperitoneal); the aerosol challenge is the most useful route, if evaluating MCMs for biodefense purposes. Choosing a representative B. pseudomallei challenge strain is problematic because there is a high degree of genetic and phenotypic variability among B. pseudomallei isolates (Ronning et al. 2010; Van Zandt et al. 2012; Sarovich et al. 2014; Welkos et al. 2015; Trevino et al. 2018). There is also a lack of understanding of the impact of strain variation on virulence, pathogenicity and mortality in mice; although some studies seek to further define this (Massey et al. 2014; Sahl et al. 2015). New information about novel strains adds to this body of literature, thus further characterizing the murine experimental model of melioidosis and its alignment to human disease.

The purpose of the present proof of concept study was to characterize, for the first time, the virulence and pathogenicity of B. pseudomallei strain NCTC 13392 (Sahl et al. 2013) in a BALB/c aerosol infection model. This novel murine model provides the opportunity to study subacute disease (a disease state between acute and chronic) alongside acute disease in the same experiment following exposure to different aerosolized dosages of bacteria. Initially a 14-day virulence study was performed followed by a 30-day pathogenesis study; clinical score, weight, bacterial burden and histopathology are reported.

Materials and methods

Bacterial strain

Burkholderia pseudomallei strain NCTC 13392, was obtained from PHE, Culture Collections, Porton Down, Salisbury, UK. This strain was originally isolated from a septicaemic, diabetic patient with fatal melioidosis, in Khon Kaen, Thailand in 1996 at the same time as strain K96243 (Sahl et al. 2013). Whole genome sequencing was performed, on the isolate used in this study, using an Illumina HiSeq system.

Experimental animals

Healthy BALB/c female mice (purchased from UK Home Office accredited suppliers, Charles Rivers UK, Ltd and Envigo CRS Ltd, UK) were used, aged 10–12 weeks and weighing 18 g or more at the time of challenge. They were group housed in cages in accordance with the UK Home Office Code of Practice for the Housing and Care of
Acute and subacute melioidosis in BALB/c mice

S.G.P. Funnell et al.

Animals Bred, Supplied or Used for Scientific Procedures (December 2014) at Advisory Committee on Dangerous Pathogens (ACDP) containment level 3 and provided with access to food and water ad libitum. All experimental work was conducted under the authority of a UK Home Office approved project license that had been subject to local ethical review at PHE Porton Down by the Animal Welfare and Ethical Review Body (AWERB) as required by the Home Office Animals (Scientific Procedures) Act 1986. Before the start of each experiment, animals were randomly assigned to the treatment groups in order to minimize bias.

Culture conditions

Each culture of B. pseudomallei NCTC 13392 was prepared from a fresh vial of working stock on plates of Luria–Bertani Agar (LBA). Plates were incubated for 24–48 h at 37°C. Growth from one LBA plate was suspended in 10 ml of Luria–Bertani Broth (LBB) to yield an undiluted primary seed. The primary seed was further diluted in LBB to achieve a 100 ml culture with an optical density (OD) OD_{600} of 0.1. This was incubated with orbital shaking at 175 rev min⁻¹ for 24 h at 37°C and used in the aerosol inoculation procedures.

Aerosol procedures

The 24 h LBB broth culture of B. pseudomallei NCTC 13392 was diluted in phosphate-buffered saline (PBS) to achieve the target presented doses which were nominally grouped as follows: very-high dose (≥10⁷ CFU per animal), high dose (10⁵ to <10⁶ CFU per animal), medium dose (10⁴ to <10⁵ CFU per animal) and low dose (<10⁴ CFU per animal).

All mice were exposed to a small particle aerosol (mass medium aerodynamic diameter ~1.5 μm) of bacteria in an AeroMP-Henderson apparatus. The challenge aerosol was generated using a three-jet Collison Nebuliser (BGI, Inc., Waltham, MA); the aerosol was mixed with conditioned air in the spray tube and delivered to the nose of each animal through an exposure tube in which nonanesthetized mice were held in restraint tubes. Samples of the aerosol were collected in PBS using an AGI30 glass impinger (Ace Glass, Inc., Vineland, NJ), and the mean particle size was determined with an aerodynamic particle sizer (TSI Instruments, Ltd., High Wycombe, UK). These processes were controlled and monitored from an AeroMP management platform (Biaera Technologies, Hagerstown, MD). The control animals were challenged with an aerosol produced from LBB/PBS in the same ratio as the bacterial challenge preparation. The presented dose was calculated using the results of bacterial enumeration of aerosol samples taken throughout exposure and estimates of respired volume calculated using Guyton’s formula (Guyton, 1947).

Virulence study

In order to determine the virulence of B. pseudomallei NCTC 13392, an initial short-term (14 day) survival study using 35 BALB/c mice was performed. Very high, high and medium doses were delivered by aerosol to three separate groups of 10 mice. Control mice (n = 5) were sprayed with sterile LBB/PBS broth. At 14 days postchallenge (pc), the surviving animals were killed humanely with an intraperitoneal overdose of pentobarbitone (Dolelethal, Vétoquinol UK Ltd, 140 mg kg⁻¹).

Pathogenesis study

In order to determine the pathogenicity of B. pseudomallei NCTC 13392, a longer term (30 day) study was conducted using 60 BALB/c mice. Three aerosol doses were delivered to three groups of mice: very high (n = 15 animals), high (n = 20) and low (n = 20). Groups of five mice were euthanized on scheduled days. For the very-high-dose group mice, were scheduled for euthanasia on day 1 (n = 5), day 3 (n = 5) and day 4 (n = 5). For the high-dose group, mice were euthanized on day 3 (n = 5), day 10 (n = 5), day 20 (n = 5) and day 30 (n = 5); a similar schedule was used for the low-dose group. The control animals (n = 5) were sprayed with sterile LBB/PBS and euthanized on day 14. On the day of euthanasia, organs were collected for bacterial burden and histopathological examination.

Clinical and euthanasia observations

Animals were weighed at the same time of day from the day before infection until the end of the experiment, or until death or euthanasia. Animals were examined twice daily for clinical signs of disease and scores were recorded using a ‘clinical observation score’. Monitoring of animals increased to at least four times daily during critical periods in the study (at times when septicaemia was likely to occur or as soon as clinical signs of septicaemia were detected). Clinical signs of disease were assigned a score based upon the following criteria: healthy, 0; ruffled fur, 2; arched back, 3; eyes shut, 3; immobile, 9; euthanasia or death in cage, 10. Clinical scores were not used to trigger euthanasia. In order to meet the requirement of the project license, three criteria for immediate euthanasia were used: (i) immobility defined as a lack of movement even after stimulus such as handling, (ii) neurological signs including repetitive or unusual movement, (iii) weight loss of more than 20% from baseline for more
than 24 h. If any animal reached any of these three euthanasia criteria, they were immediately euthanized using a UK Home Office approved Schedule 1 procedure.

**Bacteriology**

At necropsy, the same tissues were collected from each animal: the left lobe of the lung, the apical section of the spleen, a section from the right lateral lobe of the liver and the left section of the kidney. These tissues were frozen below −50°C. Tissue was thawed and homogenized in LBB with 1.4-mm ceramic beads in a Precellys24 tissue homogenizer (Bertin Technologies, Villeurbanne, France). Serial 10-fold dilutions of tissue homogenates were plated on LBA. Bacterial colonies were counted after incubation for 48 h at 37°C.

**Pathology studies**

Throughout the pathogenesis study, gross abnormalities were recorded. At necropsy, following the collection of samples for bacteriology, samples of lung, liver and kidney were collected for histopathological examination. They were placed in 10% neutral buffered formalin, processed routinely to paraffin wax and 3–5-µm sections cut and stained with haematoxylin and eosin (H and E).

**Statistical analysis**

The Kaplan–Meier method was used to plot the survival data from the virulence study. Differences in the number of CFUs in tissues, on different days, were determined by performing Student’s *t*-tests using 95% confidence interval on log_{10} transformed data. All combinations were tested, that is, day 10 vs day 20, day 20 vs day 30, etc.) Differences that were significant at *P* < 0.05 are reported. All analyses were done using Minitab version 16.

**Results**

**Whole-genome sequencing**

Whole-genome sequencing of the isolate used in this study was conducted by PHE for verification purposes (data not shown). The sequence showed identity (within 6–8 SNPs) with the strain supplied by PHE to Northern Arizona University, Center for Microbial Genetics and Genomis, Flagstaff, Arizona, USA who first published the genome of NCTC 13392 in 2013 (Sahl et al. 2013).

**Virulence study**

Animals exposed to the very-high dose (3.33 × 10³ CFU per animal) of aerosolized *B. pseudomallei* NCTC 13392 died (10/10) within 3 days (Fig. 1). Those challenged with the high dose (7.85 × 10² CFU per animal) survived longer, but died by day 6 pc. In the group given the medium dose (6.85 × 10¹ CFU per animal), 9 of 10 animals survived beyond the end of the experiment at 14 days. Information gained from this virulence study was used to determine the doses for the pathogenesis study.

**Pathogenesis study**

Animals exposed to the very high dose (3.04 × 10³ CFU per animal) of aerosolized *B. pseudomallei* NCTC 13392 where scheduled to be euthanized on days 1 (n = 5), 3 (n = 5) and 4 (n = 5) pc; however, some animals in the day 4 group met euthanasia criteria early, on day 3, and were thus included in the day 3 group (n = 8). This meant only two animals remained and they were euthanised on day 4, as planned. Those challenged with the high dose (1.11 × 10² CFU per animal) survived to the end of the study (day 30). Those animals in the low-dose group (7.69 × 10⁰ CFU per animal) also survived to the end of the study.

**Clinical signs**

In the pathogenesis study, all 15 animals challenged with a very high dose of *B. pseudomallei* developed high
clinical scores (8-4) and progressed rapidly to death (Fig. 2a). Ruffled fur was present from 24 h pc, followed by lethargy with arched backs which progressed to immobility or death by 3–4 days in all the animals. Animals (n = 20) exposed to the high dose developed clinical signs at day 3 pc that abated slightly until day 5 when signs re-emerged and the health of animals deteriorated slowly, with ruffled fur and arched backs being common (Fig. 2a). The mean individual clinical score increased to 7 by the end of the study (day 30 pc), when the remaining animals (5/5) were killed humanely. Animals (n = 20) exposed to the low dose displayed few clinical signs initially (2/5 animals had ruffled fur); these abated until day 20 pc. From day 20 pc, the mean individual clinical score began to increase, reaching 3-2 on day 30 pc (5/5 animals had ruffled fur and 2/5 animals had arched backs). Animals in the control group (5/5), killed humanely on day 14 pc, remained free of clinical signs throughout the study (data not shown).

Body weight
Animals in the very-high-dose group lost up to 18% of body weight, compared to baseline levels, within 3 days following challenge (Figure 2b). Animals challenged with the high dose lost 7% of their body weight by day 3 but then regained (5%) weight quickly within 24 h, afterwards there was a slow, consistent weight loss for the next 15 days. Weight change in the low-dose group was similar to animals in the control group (Figure 2b) up to day 14. On day 20, an increase in weight (6%) was observed compared to baseline levels; however, after this animals lost 10% of their body weight by day 30 (4% lower than at the start of the experiment).

Bacteriological studies
In the very-high-dose group, of the four tissues tested, the highest mean concentration of bacteria was in the lung (2.2 × 10^5 CFU per mg) on day 1 (Figure 3). By days 3–4 pc this significantly (P < 0.05) rose to an average of 3.9 × 10^5 CFU per mg (9/10 animals). In the spleen, kidney and liver (10/10 animals), bacteria were present at low levels (≤8 CFU per mg) on day 1, increasing significantly (P < 0.05) by days 3–4 to means of 1.2 × 10^4, 1.9 × 10^5 and 3.0 × 10^5 CFU per mg tissue respectively.

In the high-dose group, bacteria were detected in 4 of 5 animals in the lung and in 1 of 5 animals in the spleen on day 3 pc. Bacterial numbers in the spleen (5/5) increased significantly (P < 0.001) peaking on day 20 (average 2.5 × 10^4 CFU per mg), whereas bacterial counts decreased (5/5) in the lung by day 20 (≤1 CFU per mg). Between days 20 and 30 pc, there was a rise in bacterial counts in the lung, peaking at an average 1.9 × 10^5 CFU per mg. In the spleen a significant (P < 0.05) reduction in the mean number of bacteria was observed (mean, 9.7 × 10^7 CFU per mg). Throughout the course of the study there was a gradual rise in the number of bacteria in the kidney and liver; by day 30 pc these had reached mean levels of 2.7 × 10^2 and 4.6 × 10^2 CFU per mg respectively.

In the low-dose group, only 1 of 5 animals had detectable levels of bacteria in the lungs (3.9 × 10^3 CFU per mg) at 3 days pc and 1 of 5 animals on day 10 pc.
Bacteria were not detected on day 20 pc in 5 of 5 animals (≤1 CFU per mg, limit of detection) in the lungs. However, by day 30 pc, infection was re-established in the lungs of 2 of 5 animals (mean 1×10^5 CFU per mg, n = 2). Similarly in the kidney, bacteria (2×10^4 CFU per mg) were present in 1 of 5 animals on day 3 pc and in 1 of 5 animals (3×10^4 CFU per mg) on day 10 pc. Bacteria were not detected on day 20 pc, but again infection was re-established in 4 of 5 animals by day 30 (2×10^5 CFU per mg, n = 4). No bacteria were detected in the liver or spleen on days 3 and 10 pc; however, by day 20, bacteria were found in 2 of 5 animals (mean 1×10^3 CFU per mg, n = 2) in the spleen and in 1 of 5 animals in the liver of 3×10^4 CFU per mg). By day 30 pc, 3 of 5 and 2 of 5 animals had bacteria in the spleen and liver respectively. *Burkholderia pseudomallei* were not isolated from the tissues of control animals.

Histopathology findings

The findings for all groups are summarized in Table 1. Five lesion types were seen in lung that were associated with infection with *B. pseudomallei*. These comprised: parenchymal, multifocal pyogranulomatous inflammation, with either central necrosis (A), or the lesions were non-necrotic (B); patchy, interstitial, histiocytic inflammation, variably accompanied by neutrophils (C); bronchial and bronchiolar inflammatory cell infiltrates (D); and bronchial and bronchiolar epithelial cell necrosis (E). In the spleen, multifocal, necrotizing splenitis with neutrophils ± lymphocytes, with cellular degeneration (necrosis/apoptosis) (F), and large, well-demarcated pyogranulomatous foci (abscesses) (G), were observed. In the liver, two lesions were noted, namely random, multifocal, necrotizing hepatitis ± neutrophils (H), and hepatocyte degeneration and focal inflammatory cell infiltrate (I).
Very-high-dose group

No animal survived beyond day 4 pc. In the lung at day 1, lesions B–E were present with varying frequency (Fig. 4a). Necrosis was not observed within pyogranulomas (A) until day 3 pc (Fig. 4b). In the spleen, changes were absent on day 1 pc. By days 3 and 4 pc, necrotizing splenitis (F) was the only lesion type observed, and present in a proportion of animals (Fig. 4c). In the liver, necrotizing hepatitis (H) was seen in a proportion of animals at each time point pc (Fig. 4d).

High-dose group

Lesions were assessed at 3, 10, 20 and 30 days pc. Lung lesions A and B, namely pyogranulomatous inflammation in the presence or absence of necrosis, were common at day 3 pc and less common subsequently (Fig. 5a). In contrast, lesions C–E were observed frequently at the later time points. In the spleen, necrotizing splenitis (F) was limited to one animal at day 20 pc. Pyogranulomas (G) were not seen at day 3 pc, but were common at days 10, 20 and 30 (Fig. 5b). In the liver, both lesion types H and I were seen frequently at all time points pc.

Low-dose group

Lesions were assessed at 3, 10, 20 and 30 dpc. In the lung, interstitial histiocytic inflammation (C) was the most frequently observed lesion type at all time points. The remaining changes were seen occasionally (Figure 5c, d). In the spleen, both splenitis (F) and pyogranulomas (G) were present at all time points. In the liver, both lesion types H and I were seen frequently at all time points pc. Histopathological changes were not detected in the kidney in any animal in any group.

Discussion

Well-characterized animal models are needed to better understand the pathogenic process of infection by aerosolized B. pseudomallei (Massey et al. 2014). Animal models are also needed to help evaluate the efficacy of novel therapeutics because Phase III human clinical trials are difficult to perform. This study reports on, for the first time, the virulence and pathogenicity of B. pseudomallei NCTC 13392 in BALB/c mice where both acute and subacute disease were observed following challenge with different aerosolized doses of bacteria.

Table 1 Histological features of pathogenesis study. A summary of treatment-related changes in the lung, spleen and liver on different days. Number of animals with treatment-related changes/total number of animals. No changes were observed in the kidney of any animal in any group

| Organ     | Lesion                                | Exposure dose (no. of animals with treatment-related changes/total no. of animals) |
|-----------|---------------------------------------|----------------------------------------------------------------------------------|
|           |                                       | Days postchallenge                                                               |
|           |                                       | Very high dose | High dose | Low dose |
| Lung      | Parenchymal, multifocal, necrotizing,  | 1   | 3   | 4   | 3   | 10  | 20  | 30  |
|           | pyogranulomatous inflammation         | 0/4 | 3/4 | 2/4 | 2/4 | 0/4 | 1/4 | 1/4 |
|           | Parenchymal, multifocal,               | 5/4 | 8/4 | 2/4 | 5/4 | 5/4 | 5/4 | 5/4 |
|           | pyogranulomatous inflammation         | 5/4 | 5/4 | 0/4 | 3/4 | 0/4 | 1/4 | 1/4 |
|           | Patchy, interstitial histiocytic       | 5/4 | 5/4 | 2/4 | 3/4 | 2/4 | 5/4 | 4/4 |
|           | inflammation ± neutrophils             | 5/4 | 8/4 | 2/4 | 5/4 | 5/4 | 5/4 | 5/4 |
|           | Bronchial/bronchiolar inflammatory cell exudates | 4/4 | 7/4 | 2/4 | 3/4 | 0/4 | 1/4 | 2/4 |
|           | Bronchial/bronchiolar epithelial cell necrosis | 1/4 | 3/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 |
| Spleen    | Multifocal, necrotizing splenitis      | 5/4 | 8/4 | 2/4 | 5/4 | 5/4 | 5/4 | 5/4 |
|           | with neutrophils ± lymphocyte necrosis/apoptosis | 5/4 | 8/4 | 2/4 | 5/4 | 5/4 | 5/4 | 5/4 |
|           | Large, well-demarcated pyogranulomatous foci (abscess) | 5/4 | 8/4 | 2/4 | 5/4 | 5/4 | 5/4 | 5/4 |
| Liver     | Random, multifocal, necrotizing hepatitis ± neutrophils | 5/4 | 8/4 | 2/4 | 5/4 | 5/4 | 5/4 | 5/4 |
|           | Hepatocyte degeneration and            | 5/4 | 8/4 | 2/4 | 5/4 | 5/4 | 5/4 | 5/4 |
|           | focal inflammatory cell infiltrate     | 5/4 | 8/4 | 2/4 | 5/4 | 5/4 | 5/4 | 5/4 |
Figure 4 Pathogenesis study: Examples of lesions. (a) Lung, very-high-dose group, 1 day pc. Focal, pyogranulomatous inflammation. (b) Lung, very-high-dose group, 3–4 days pc. Focal, necrotizing, pyogranulomatous inflammation. (c) Spleen, very-high-dose group, 3–4 days pc. Multifocal, coalescing, necrotizing splenitis in the red and white pulp. (d) Liver, very-high-dose group, day 1 pc. Focal, necrotizing hepatitis (All sections stained with haemotoxylin and eosin). [Colour figure can be viewed at wileyonlinelibrary.com]

Figure 5 Pathogenesis Study: Examples of lesions. (a) Lung, high-dose group, day 10 pc. Patchy, interstitial, histiocytic cell infiltration of alveolar walls, with scattered neutrophils. (b) Spleen, high-dose group, 10 days pc. Coalescing, large, well-demarcated, pyogranulomatous foci (abscesses). (c) Lung, low-dose group, 3 days pc. Prominent, bronchial and bronchiolar inflammatory cell exudates, comprising primarily neutrophils, filling lumena (arrow), surrounded by necrotizing, pyogranulomatous inflammation. (d) Lung, low-dose group, 10 days pc. Well-demarcated, pyogranuloma (abscess) surrounded by fibrosis and inflammatory cells (All sections stained with haemotoxylin and eosin). [Colour figure can be viewed at wileyonlinelibrary.com]
Acute and subacute melioidosis in BALB/c mice

S.G.P. Funnell et al.

Acute disease was observed when BALB/c mice were challenged with a very high dose (>10^5 CFU per animal) of *B. pseudomallei* NCTC 13392. Animals succumbed to the disease very quickly and died within 3–4 days following exposure. Acute disease was characterized by mean high individual clinical scores of 8-4 (comprising ruffled fur, arched backs and lethargy) and weight loss (up to 18%). In people, acute disease is characterized by a range of symptoms including weight loss, fever, pneumonia, sepsis and death (Currie et al. 2000; Boruah et al. 2013; Cheng et al. 2013; Jin and Ning, 2014). In people, the lung is the most commonly affected organ. Changes in the lung, described in the current study, are similar to those observed in human disease, where the initial presenting signs are associated with pneumonia or primary lung abscesses (White, 2003).

In addition to the lung, in humans, seeding and abscess formation can arise in any organ; the liver, spleen, skeletal muscle and prostate being common sites (White 2003). A recent fatal case of melioidosis, describes how a male suffered a fever for a week prior to death and at postmortem the lung, liver and spleen contained multiple microabscesses (<1 cm diameter) and neutrophilic infiltration with occasional giant cells (Tan et al. 2019), all sites were microbiological culture positive for *B. pseudomallei*. Similarly, in the present study, during acute disease, bacteria were found in the spleen, liver, kidney and the highest bacterial burden (3.9 x 10^7 CFU per mg) was in the lungs of mice, on days 3–4 pc. The pathological changes in the mouse lung, seen here, are similar to those described in human disease (White, 2003). Overall many of the pathogenic characteristics of *B. pseudomallei* NCTC 13392 infection in the present mouse study align with those seen in acute human disease, demonstrating that this bacterial strain, aerosolized dose and mouse model are suitable for evaluating MCMs against acute melioidosis.

The characteristics of subacute melioidosis were also observed in the present study when BALB/c mice were exposed to a low dose of NCTC 13392 (<10 CFU per animal). Here, low clinical scores (≤1-2) were observed initially; these subsided until day 20 pc. Afterwards clinical scores began to increase to a mean of 3-2 by day 30 pc, weight loss (4%) was also seen. This pattern of symptoms mimicks human subacute/chronic infection; in humans, chronic melioidosis is characterized as a symptomatic infection that lasts >2 months; the nonspecific signs and symptoms, during the incubation period, can often hinder the diagnosis and treatment of this disease (Wiersinga et al. 2018). In this study, on day 10 pc, hepatic abscesses were present and hepatic degeneration and inflammation was observed, which is consistent with subacute/chronic infection. On day 30 pc, bacteria were found in multiple sites and microscopic lesions (pyogranulomas/abscesses), attributable to *B. pseudomallei* infection, were noted in most mice. This is consistent with human subacute/chronic disease, where abscesses in different organs are seen (White, 2003). In the present proof of concept study a model for subacute human infection is described, and thus therapeutics could be prescreened to assess their effectiveness against subacute/chronic disease. The model requires further refinement and would benefit from larger animal numbers per treatment group to enable statistical significance and also a longer study duration (e.g. 60 days).

In the present pathogenesis study, BALB/c survivors exposed to the low and high dose showed clinical signs, histological features of infection and weight loss by day 30; these are clearly indicators of a subacute infection. If this study was longer in duration then these animals may have fully succumbed to the disease and died. The subacute characteristic of *B. pseudomallei* NCTC 13392 has made the accurate estimation of an LD50 for this strain difficult to ascertain. Using the virulence study data (14 day duration) an estimated LD50 of approximately 200 CFU could be determined; however, the data obtained from the 30-day duration pathogenesis experiment indicates that an LD50 of <8 CFU should be used for NCTC 13392. The true LD50, however, can only be found by performing a study with a longer observation period (e.g. 60–100 days). Other researchers have also noted a lowering of LD50 values, in mice, when they compared the LD50 results from 21-day and 60-day duration intraperitoneal infection studies with other strains of *B. pseudomallei* (Welkos et al. 2015). Recent low-dose, aerosol challenge studies comparing different clinical isolates of *B. pseudomallei* in BALB/c mice describe an LD50 value of 25-1 CFU for K96243 (prototype strain), 0.99 CFU for HBPUB10134a and 0.35 CFU for MSHR5855 (Trevino et al. 2018). A working hypothesis is that the virulence of NCTC 13392 falls somewhere between these strains. A property of NCTC 13392 in particular, is that the LD50 is likely to be inversely proportional to the study length due to its subacute characteristics, at low dose. The bacterial burden in the lungs and spleens of BALB/c mice infected with HBPUB10134a and MSHR5855 (delivered by aerosol with doses 6 CFU and 1-2 CFU respectively) is higher than mice infected with a low dose (8 CFU) of NCTC 13392 at day 10 pc, indicating that the infection caused by these other two strains, at low doses, becomes established more quickly (Trevino et al. 2018).

Currently most MCMs for melioidosis are evaluated in animal models for their effectiveness against acute disease; the mouse model being the most widely used (Warawa, 2010) although larger animal models have been...
evaluated for instance: Rhesus macaques (Yingst, Face-mire et al. 2014); African Green monkeys (Yeager et al. 2012) and marmosets (Nelson et al. 2011; Nelson et al. 2014; Nelson et al. 2015). Aerosolized doses of <10 CFU per animal \(B.\) pseudomallei NCTC 13392 caused a lethal infection by day 3–4 in marmosets, indicating these animals are highly susceptible to this strain (Nelson et al. 2011; Erratum, 2013). Overall there is a need to focus on defining acute disease and developing MCMs because of the potential for \(B.\) pseudomallei to be used as a biological weapon (Kwon et al. 2018). Studies on aerosol delivery are particularly important to help characterize the natural history of inhalational exposure to \(B.\) pseudomallei in a deliberate-release scenario, where the inoculum is likely to be much higher than exposure from an environmental source (Gilad et al. 2007). Fewer MCMs are tested for their effectiveness against chronic disease and it remains unclear whether treatment recommendations for this condition remain the same as for acute melioidosis (Currie et al. 2000; Nandi and Tan, 2013). Chronic disease is usually a public health concern often arising from a low-dose environmental exposure in a country where this disease is endemic. There are fewer animal models for subacute/chronic melioidosis (Warawa, 2010; Conejero et al. 2011; Soffler et al. 2012; Amemiya et al. 2015; Bearss et al. 2017).

In conclusion, the present proof of concept study has, for the first time, shown that \(B.\) pseudomallei NCTC 13392 is virulent and lethality is dose dependant, when delivered by aerosol to BALB/c mice; thus, this strain is suitable for use in MCM evaluation studies. Both acute and subacute melioidosis disease can also be modelled with this strain by adjusting the challenge dose. Following further refinement, this combination of mouse strain, bacterial strain and dosing regime, will provide a useful toolkit for the preliminary screening of the effectiveness of novel vaccines or therapeutics for both acute and subacute melioidosis, at the same time.

**Acknowledgements**

The authors gratefully acknowledge the support from the Biological Investigations Group, the BPEG Bacteriology group and the Histology department at the National Infection Service, PHE, Porton Down, United Kingdom. The authors also fully appreciate assistance with whole-genome sequencing and analysis from Professor Sharon Peacock, University of Cambridge and Dr Michael Elmore, Dr Edward Burnett and Dr Julie Russell from PHE, Porton Down. The views expressed in this paper are those of the authors and not necessarily those of the funding body. This work was fully funded by NIAID [contract number: N01-A1-30062 Task Order C19].

**Conflicts of Interest**

No conflicts of interest declared.

**References**

Amemiya, K., Dankmeyer, J.L., Fetterer, D.P., Worsham, P.L., Welkos, S.L. and Cote, C.K. (2015) Comparison of the early host immune response to two widely diverse virulent strains of \(Burkholderia\) pseudomallei that cause acute or chronic infections in BALB/c mice. *Microb Pathog* 86, 53–63.

Bearss, J.J., Hunter, M., Dankmeyer, J.L., Fritts, K.A., Klimko, C.P., Weaver, C.H., Shoe, J.L., Quirk, A.V. et al. (2017) Characterization of pathogenesis of and immune response to \(Burkholderia\) pseudomallei K96243 using both inhalational and intraperitoneal infection models in BALB/c and C57BL/6 mice. *PLoS ONE* 12, e0172627.

Boruah, D.K., Prakash, A., Bora, R. and Buragohain, L. (2013) Acute pulmonary melioidosis in a child: a case report and review of literature. *Indian J Radiol Imaging* 23, 310–312.

Cheng, A.C., Currie, B.J., Dance, D.A., Funnell, S.G., Limmathurotsakul, D., Simpson, A.J. and Peacock, S.J. (2013) Clinical definitions of melioidosis. *Am J Trop Med Hyg* 88, 411–413.

Conejero, L., Patel, N., De Reynal, M., Oberdorf, S., Prior, J., Felgner, P.L., Titball, R.W., Salguero, F.J. et al. (2011) Low-dose exposure of C57BL/6 mice to \(Burkholderia\) pseudomallei mimics chronic human melioidosis. *Am J Pathol* 179, 270–280.

Currie, B.J., Fisher, D.A., Anstey, N.M. and Jacups, S.P. (2000) Melioidosis: acute and chronic disease, relapse and reactivation. *Trans R Soc Trop Med Hyg* 94, 301–304.

Erratum (2013) Erratum. *Int J Exp Pathol* 94, 74.

Gilad, J., Harary, I., Dushnitsky, T., Schwartz, D. and Amsalem, Y. (2007) \(Burkholderia\) mallei and \(Burkholderia\) pseudomallei as bioterrorism agents: national aspects of emergency preparedness. *Isr Med Assoc J* 9, 499–503.

Guyton, A.C. (1947) Measurement of the respiratory volumes of laboratory animals. *Am J Physiol* 150, 70–77.

Hoppe, I., Brenneke, B., Rohde, M., Kreft, A., Haussler, S., Reganzerowski, A. and Steinmetz, I. (1999) Characterization of a murine model of melioidosis: comparison of different strains of mice. *Infect Immun* 67, 2891–900.

Jeddeloh, J.A., Fritz, D.L., Waag, D.M., Hartings, J.M. and Andrews, G.P. (2003) Biodefense-driven murine model of pneumatic melioidosis. *Infect Immun* 71, 584–587.

Jin, J.L. and Ning, Y.X. (2014) Septicemic melioidosis: a case report and literature review. *J Thorac Dis* 6, E1–E4.
Kunnathuparambil, S.G., Sathar, S.A., Tank, D.C., Sressh, S., Mukunda, M., Narayanan, P. and Vinayakumar, K.R. (2013) Splenic abscess due to chronic melioidosis in a patient previously misdiagnosed as tuberculosis. *Ann Gastroenterol* **26**, 77–79.

Kwon, E.H., Reisler, R.B., Cardile, A.P., Cieslak, T.J., D’Onofrio, M.J., Hewlett, A.L., Martins, K.A., Ritchie, C. et al. (2018) Distinguishing respiratory features of category A/B potential bioterrorism agents from community-acquired pneumonia. *Health Secur* **16**, 224–238.

Lafontaine, E.R., Zimmerman, S.M., Shaffer, T.L., Michel, F., Gao, X. and Hogan, R.J. (2013) Use of a safe, reproducible, and rapid aerosol delivery method to study infection by *Burkholderia pseudomallei* and *Burkholderia mallei* in mice. *PLoS ONE* **8**, e76804.

Leaky, A.K., Ulett, G.C. and Hirst, R.G. (1998) BALB/c and C57Bl/6 mice infected with virulent *Burkholderia pseudomallei* provide contrasting animal models for the acute and chronic forms of human melioidosis. *Microb Pathog* **24**, 269–275.

Lever, M.S., Nelson, M., Stagg, A.J., Beedham, R.J. and Simpson, A.J. (2009) Experimental acute respiratory *Burkholderia pseudomallei* infection in BALB/c mice. *J Exp Pathol* **90**, 16–25.

Liang, C.C., Chen, S.Y., Chen, T.Y. and Chen, S.T. (2016) Central nervous system melioidosis mimics malignancy: a case report and literature review. *World Neurosurg* **89**, 732.e19–23.

Limmathurotsakul, D., Golding, N., Dance, D.A., Messina, J.P., Pigott, D.M., Moyes, C.L., Rolim, D.B., Bettherat, E. et al. (2016) Predicted global distribution of *Burkholderia pseudomallei* and burden of melioidosis. *Nat Microbiol* **1**, 15008.

Liu, B., Koo, G.C., Yap, E.H., Chua, K.L. and Gan, Y.H. (2002) Model of differential susceptibility to mucosal *Burkholderia pseudomallei* infection. *Infect Immun* **70**, 504–511.

Massey, S., Yeager, L.A., Blumentritt, C.A., Vijayakumar, S., Sbrana, E., Peterson, J.W., Brasil, T., Leduc, J.W. et al. (2014) Comparative *Burkholderia pseudomallei* natural history virulence studies using an aerosol murine model of infection. *Sci Rep* **4**, 4305.

Nandi, T. and Tan, P. (2013) Less is more: *Burkholderia pseudomallei* and chronic melioidosis. *MBio* **4**, e00709–13.

Nelson, M., Dean, R.E., Salguero, F.J., Taylor, C., Pearce, P.C., Simpson, A.J. and Lever, M.S. (2011) Development of an acute model of inhalational melioidosis in the common marmoset (*Callithrix jacchus*). *Int J Exp Pathol* **92**, 428–435.

Nelson, M., Salguero, F.J., Dean, R.E., Ngugi, S.A., Smither, S.J., Atkins, T.P. and Lever, M.S. (2014) Comparative experimental subcutaneous glands and melioidosis in the common marmoset (*Callithrix jacchus*). *Int J Exp Pathol* **95**, 378–391.

Nelson, M., Nunez, A., Ngugi, S.A., Sinclair, A. and Atkins, T.P. (2015) Characterization of lesion formation in marmosets following inhalational challenge with different strains of *Burkholderia pseudomallei*. *Int J Exp Pathol* **96**, 414–426.

Ngauy, V., Lemshev, Y., Sadkowski, L. and Crawford, G. (2005) Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. *J Clin Microbiol* **43**, 970–972.

Peacock, S.J., Limmathurotsakul, D., Lubell, Y., Koh, G.C., White, L.J., Day, N.P. and Titball, R.W. (2012) Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. *PLoS Negl Trop Dis* **6**, e1488.

Pitman, M.C., Luck, T., Marshall, C.S., Anstey, N.M., Ward, L. and Currie, B.J. (2015) Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm. *PLoS Negl Trop Dis* **9**, e0003586.

Ronning, C.M., Losada, L., Brinkac, L., Inman, J., Ulrich, R.L., Schell, M., Nierman, W.C. and Deshazer, D. (2010) Genetic and phenotypic diversity in *Burkholderia*: contributions by prophage and phage-like elements. *BMC Microbiol* **10**, 202.

Sahl, J.W., Stone, J.K., Gelhaus, H.C., Warren, R.L., Crutwell, C.J., Funnell, S.G., Keim, P. and Tuanyok, A. (2013) Genome sequence of *Burkholderia pseudomallei* NCTC 13392. *Genome Announc* **1**, 3.

Sahl, J.W., Allender, C.J., Colman, R.E., Calif, K.J., Schupp, J.M., Currie, B.J., Van Zandt, K.E., Gelhaus, H.C. et al. (2015) Genomic characterization of *Burkholderia pseudomallei* isolates selected for medical countermeasures testing: comparative genomics associated with differential virulence. *PLoS ONE* **10**, e0121052.

Sarovich, D.S., Price, E.P., Webb, J.R., Ward, L.M., Voutsinos, M.Y., Tuanyok, A., Mayo, M., Kaestli, M. et al. (2014) Variable virulence factors in *Burkholderia pseudomallei* (melioidosis) associated with human disease. *PLoS ONE* **9**, e91682.

Soffler, C., Bosco-Lauth, A.M., Aboellail, T.A., Marolf, A.J. and Bowen, R.A. (2012) Development and characterization of a caprine aerosol infection model of melioidosis. *PLoS ONE* **7**, e43207.

Tan, G.Y., Liu, Y., Sivalingam, S.P., Sim, S.H., Wang, D., Paucod, J.C., Gauthier, Y. and Ooi, E.E. (2008) *Burkholderia pseudomallei* aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice. *J Med Microbiol* **57**, 508–515.

Tan, R.Z., Mohd Nor, F., Shadie, S. and Tan, L.J. (2019) Melioidosis mimicking miliary tuberculosis. *Forensic Sci Med Pathol* **15**, 151–154.

Thomas, R.J., Davies, C., Nunez, A., Hibbs, S., Eastaugh, L., Harding, S., Jordan, J., Barnes, K. et al. (2012) Particle-size dependent effects in the BALB/c murine model of inhalational melioidosis. *Front Cell Infect Microbiol* **2**, 101.
Tittball, R.W., Russell, P., Cuccui, J., Easton, A., Haque, A., Atkins, T., Sarkar-Tyson, M., Harley, V. et al. (2008) *Burkholderia pseudomallei*: animal models of infection. *Trans R Soc Trop Med Hyg* **102**(Suppl. 1), S111–S116.

Trevino, S.R., Klimko, C.P., Reed, M.C., Aponte-Cuadrado, M.I., Hunter, M., Shoe, J.L., Meyer, J.R., Dankmeyer, J.L. et al. (2018) Disease progression in mice exposed to low-doses of aerosolized clinical isolates of *Burkholderia pseudomallei*. *PLoS ONE* **13**, e0208277.

Van Zandt, K.E., Tuanyok, A., Keim, P.S., Warren, R.L. and Gelhaus, H.C. (2012) An objective approach for *Burkholderia pseudomallei* strain selection as challenge material for medical countermeasures efficacy testing. *Front Cell Infect Microbiol* **2**, 120.

Warawa, J.M. (2010) Evaluation of surrogate animal models of melioidosis. *Front Microbiol* **1**, 141.

Welkos, S.L., Klimko, C.P., Kern, S.J., Bearss, J.I., Bozue, J.A., Bernhards, R.C., Trevino, S.R., Waag, D.M. et al. (2015) Characterization of *Burkholderia pseudomallei* strains using a murine intraperitoneal infection model and in vitro macrophage assays. *PLoS ONE* **10**, e0124667.

West, T.E., Myers, N.D., Limmathurotsakul, D., Liggitt, H.D., Chantratita, N., Peacock, S.J. and Skerrett, S.J. (2010) Pathogenicity of high-dose enteral inoculation of *Burkholderia pseudomallei* to mice. *Am J Trop Med Hyg* **83**, 1066–1069.

West, T.E., Myers, N.D., Liggitt, H.D. and Skerrett, S.J. (2012) Murine pulmonary infection and inflammation induced by inhalation of *Burkholderia pseudomallei*. *Int J Exp Pathol* **93**, 421–428.

White, N.J. (2003) Melioidosis. *Lancet* **361**, 1715–1722.

Wiersinga, W.J., Van der Poll, T., White, N.J., Day, N.P. and Peacock, S.J. (2006) Melioidosis: insights into the pathogenicity of *Burkholderia pseudomallei*. *Nat Rev Microbiol* **4**, 272–282.

Wiersinga, W.J., Virk, H.S., Torres, A.G., Currie, B.J., Peacock, S.J., Dance, D.A.B. and Limmathurotsakul, D. (2018) Melioidosis. *Nat Rev Dis Primers* **4**, 17107.

Wong, K.T., Puthucheary, S.D. and Vadivelu, J. (1995) The histopathology of human melioidosis. *Histopathology* **26**, 51–55.

Yeager, J.J., Facemire, P., Dahirsch, P.A., Robinson, C.G., Nyakiti, D., Beck, K., Baker, R. and Pitt, M.L. (2012) Natural history of inhalation melioidosis in rhesus macaques (*Macaca mulatta*) and African green monkeys (*Chlorocebus aethiops*). *Infect Immun* **80**, 3332–3340.